POLE P286R

CI-VAR-00003329Explore in graph →NP_006222.2:p.Pro286ArgNM_006231.3:c.857C>GClinVar 376500 CIViC 1830 rs1057519943

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
POLE P286R	(prognostic)	Prognostic	B	Supports Better Outcome	3	accepted	EID5017 POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis. PMID 28404093 · Domingo et al., 2016 · Open in CIViC	civic
Malignant Endometrial Neoplasm1
POLE P286R	(prognostic)	Prognostic	A	Supports Better Outcome	5	submitted	EID13113 In the PORTEC-3 trial cohort, POLE-ultramutated (POLEmut) endometrial carcinomas had a 98% five-year recurrence-free survival, independent of the adjuvant treatment arm. Variant P286R is the most comm… (full text at CIViC) PMID 32749941 · León-Castillo et al., 2020 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376500	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Programmed death ligand-1 (PD-L1) blocking antibody response; Endometrioid adenocarcinoma; Hereditary cancer-predisposing syndrome	germline/somatic	4	Feb 05, 2025	clinvar